All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Sara Ghorashian, University College London, London, UK. We asked, What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
The COVID-19 pandemic has had an impact on the logistics of the already complex delivery of chimeric antigen receptor (CAR) T-cell therapies, by delaying both clinical studies and CAR T-cell accreditation for many centers. Ghorashian provides an overview of the challenges faced and dimensions to consider for the future, including vaccination, complications, and disease context.
Management of COVID-19 outbreak on transplant wards
The Multiple Myeloma Hub presents an article based on a webinar arranged by the EBMT and ASTCT titled “Strategies to prevent and handle outbreak of COVID-19 on transplant wards”.
How do I manage the risk of infection in patients treated with immunotherapies?
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage...
Subscribe to get the best content related to multiple myeloma delivered to your inbox